Merck & Co., Inc. (MRK) Position Trimmed by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 2.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,332,174 shares of the company’s stock after selling 35,972 shares during the quarter. Merck & Co., Inc. accounts for about 1.2% of Tocqueville Asset Management L.P.’s portfolio, making the stock its 8th largest holding. Tocqueville Asset Management L.P.’s holdings in Merck & Co., Inc. were worth $94,504,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of MRK. Chemung Canal Trust Co. boosted its stake in Merck & Co., Inc. by 82.2% in the 3rd quarter. Chemung Canal Trust Co. now owns 107,279 shares of the company’s stock worth $7,610,000 after purchasing an additional 48,395 shares during the period. Third Point LLC acquired a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $319,230,000. Bollard Group LLC boosted its stake in Merck & Co., Inc. by 2.4% in the 2nd quarter. Bollard Group LLC now owns 100,829 shares of the company’s stock worth $6,120,000 after purchasing an additional 2,385 shares during the period. Worldquant Millennium Quantitative Strategies LLC acquired a new position in Merck & Co., Inc. in the 2nd quarter worth approximately $23,693,000. Finally, Epoch Investment Partners Inc. boosted its stake in Merck & Co., Inc. by 73.2% in the 2nd quarter. Epoch Investment Partners Inc. now owns 4,635,471 shares of the company’s stock worth $281,373,000 after purchasing an additional 1,959,318 shares during the period. Hedge funds and other institutional investors own 72.58% of the company’s stock.

A number of equities analysts recently commented on MRK shares. Citigroup raised their price objective on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st. SunTrust Banks raised their price objective on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, October 29th. Zacks Investment Research raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research note on Wednesday, September 26th. Guggenheim started coverage on shares of Merck & Co., Inc. in a research note on Monday, October 8th. They set a “buy” rating for the company. Finally, ValuEngine raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $73.32.

Shares of NYSE:MRK opened at $74.90 on Monday. The firm has a market cap of $203.32 billion, a price-to-earnings ratio of 18.82, a P/E/G ratio of 1.82 and a beta of 0.67. Merck & Co., Inc. has a 12-month low of $52.83 and a 12-month high of $80.19. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.44 and a quick ratio of 1.15.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, October 25th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $10.79 billion during the quarter, compared to analyst estimates of $10.87 billion. Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.48%. Equities analysts forecast that Merck & Co., Inc. will post 4.34 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, January 8th. Stockholders of record on Monday, December 17th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, December 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.94%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.48. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 55.28%.

Merck & Co., Inc. declared that its board has authorized a share repurchase plan on Thursday, October 25th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 5.1% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

In other news, EVP Adam H. Schechter sold 277,879 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $73.81, for a total transaction of $20,510,248.99. Following the transaction, the executive vice president now owns 277,879 shares in the company, valued at approximately $20,510,248.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Roger M. Perlmutter sold 225,443 shares of the firm’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $75.27, for a total transaction of $16,969,094.61. Following the transaction, the insider now owns 366,998 shares in the company, valued at approximately $27,623,939.46. The disclosure for this sale can be found here. Insiders have sold a total of 612,043 shares of company stock worth $45,530,574 in the last 90 days. 0.32% of the stock is owned by insiders.

WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2019/01/14/merck-co-inc-mrk-position-trimmed-by-tocqueville-asset-management-l-p.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Story: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit